Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has submitted an extension application for CT-P6 SC, a subcutaneous formulation of Herzuma, to the European Medicines Agency (EMA) and the European Commission (EC) based on Phase 1 clinical trial results. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Read More “[Disclosure] Celltrion (068270) – Application for Extension of Marketing Authorization for CT-P6 SC (Herzuma Subcutaneous) in Europe / 2026-04-30” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has disclosed the previously withheld information regarding the number of trial subjects (220 patients) for its CT-P51 Phase 3 IND amendment in Korea following regulatory approval. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Disclosed Metrics and…

Read More “[Disclosure] Celltrion (068270) – Application for Amendment of Phase 3 Clinical Trial Plan for CT-P51 (Keytruda Biosimilar) in Korea (Correction) / 2026-04-24” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has confirmed approval from the Ministry of Food and Drug Safety (MFDS) in South Korea for an IND amendment application regarding the Phase 3 clinical trial of CT-P51 (a Keytruda biosimilar candidate). 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint)…

Read More “[Disclosure] Celltrion (068270) – Approval of IND Amendment for CT-P51 (Keytruda Biosimilar) Korea Phase 3 Clinical Trial / 2026-04-24” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics reported Q1 2026 consolidated revenue of KRW 1.26T and operating profit of KRW 580.8B, marking a year-over-year increase of 25.8% and 35.0%, respectively. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of External Auditor’s Audit Results and…

Read More “[Disclosure] Samsung Biologics (207940) – Consolidated Financial Results (Preliminary) / 2026-04-22” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided to acquire approximately KRW 100.0B (492,611 shares) of its own common stock through open market purchases to stabilize share price and enhance shareholder value. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Actual Execution Progress…

Read More “[Disclosure] Celltrion (068270) – Decision on Acquisition of Treasury Shares / 2026-04-22” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has expanded a contract manufacturing agreement originally disclosed in March 2026, increasing the value from KRW 279.6B to KRW 350.0B upon the client’s request. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Future Amended Disclosures Regarding Changes in…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Contract Signings for Supply and Sales / 2026-04-10” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has announced that it plans to disclose its financial results for Q1 2026 (January–March) on April 22, 2026. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Actual Release of Financial Results on the Scheduled Disclosure Date This advance…

Read More “[Disclosure] Samsung Biologics (207940) – Advance Notice of Financial Results Disclosure / 2026-04-08” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Following the retirement of 9,110,000 treasury shares, Celltrion’s total issued common shares have decreased to 221,938,261, with the modified listing effective on April 13, 2026. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Total Issued Shares Update and…

Read More “[Disclosure] Celltrion (068270) – Modification of Listing (Share Retirement) / 2026-04-08” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN will hold an Investor Relations (IR) session at Conrad Seoul (Yeouido) for domestic institutional investors to provide updates on its bio platform technologies and pipeline plans. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Platform Technologies…

Read More “[Disclosure] ALTEOGEN (196170) – Investor Relations (IR) Host / 2026-04-07” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics’ U.S. subsidiary (Samsung Biologics America) has updated the acquisition amount to approximately KRW 521.6B and finalized the scheduled acquisition date as March 31, 2026, for acquiring a 100% stake in Human Genome Sciences to secure a U.S. drug substance manufacturing facility. 📊 [Key Disclosure…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Decision on Acquisition of Shares and Equity Securities of Other Corporation / 2026-03-31” »